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Abstract
Background: Cardiovascular disease with disturbances in the haemostatic system, might lead to thrombotic
complications with clinical manifestations like acute myocardial infarction (AMI) and stroke. Activation of the
coagulation cascade with subsequent increased thrombin generation, characterizes a prothrombotic phenotype. In
the present study we investigated whether prothrombotic markers were associated with risk factors and clinical
subgroups in a cohort of patients with angiographically verified coronary artery disease (CAD). The patients were
randomized to long-term treatment with the antiplatelet drugs aspirin or clopidogrel, and we further investigated
the effect on hypercoagulability of such treatment for 1 year, of which limited data exists.
Methods: Venous blood samples were collected in fasting condition between 08:00 and 10:30 am, at baseline
when all patients were on aspirin therapy (n = 1001) and in 276 patients after 1 year follow-up on aspirin or
clopidogrel. In vivo thrombin generation was assessed by prothrombin fragment 1 + 2 (F1+2) and D-dimer, and the
endogenous thrombin potentiale (ETP) in the calibrated automated thrombogram (CAT) assay, representing ex vivo
thrombin generation. In addition soluble tissue factor (sTF) and free- and total tissue factor pathway inhibitor (TFPI)
were measured.
Results: We found age to be significantly associated with F1+2 and D-dimer (β= 0.229 and β =0.417 respectively, p
<0.001, both). Otherwise, only weak associations were found. F1+2 and D-dimer were higher in women compared
to men (p <0.001 and p= 0.033, respectively). Smokers had elevated levels of ETP compared to non-smokers
(p = 0.014). Additionally, patients on renin-angiotensin system (RAS) inhibition showed significantly higher levels of
F1+2, compared to non-users (p = 0.013). Both aspirin and clopidogrel reduced levels of ETP after 12 months
intervention (p = 0.003 and p <0.001, respectively) and the levels of F1+2 were significantly more reduced on aspirin
compared to clopidogrel (p = 0.023).
Conclusions: In the present population of stable CAD, we could demonstrate a more hypercoagulable profile
among women, smokers and patients on RAS medication, assessed by the prothrombotic markers F1+2, D-dimer
and ETP. Long-term antiplatelet treatment with aspirin alone seems to attenuate thrombin generation to a greater
extent than with clopidogrel alone. The study is registered at www.clinicaltrials.gov: NCT00222261.
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Background
Cardiovascular disease (CVD) is a global burden in which
thrombotic complications play a major role [1]. The
underlying mechanism of CVD is mainly the atheroscler-
otic process, characterized by lipid accumulation in the
subendothelium causing a low graded inflammatory le-
sion and changing the phenotype of the endothelium to a
pro-inflammatory and pro-thrombotic state [2].
Disrupture of lesions expose atherogenic material into
the arterial lumen. Platelets adhere, aggregate and be-
come activated which may lead to thrombus formation.
An occluded vessel may cause clinical manifestations
like acute myocardial infarction (AMI) and stroke [3].
Expression of subendothelial tissue factor (TF) with sub-
sequent activation of the coagulation cascade generates
thrombin at the surface of activated platelets [2,3]. TF
interacts with coagulation factor VII, forming an active
complex which activates both FIX and FX. FXa is respon-
sible for the proteolytic cleavage of prothrombin to throm-
bin, resulting in formation of prothrombin fragment 1+2
(F1+2) and further the formation of fibrin. TF is abundantly
present in atherosclerotic plaques. In addition soluble TF
(sTF) may be found on monocyte- or platelet- derived
microparticles or sTF may be released from cells. The initi-
ation of coagulation is regulated by tissue factor pathway
inhibitor (TFPI) which inhibits both TF-FVIIa complex and
activated FX [4,5]. The pro- and anticoagulant balance is
essential in the prevention of thrombotic complications.
Increased levels of the haemostatic markers sTF, F1+2 and
D-dimer, the latter reflecting ongoing fibrin formation and
degradation, have been shown in patients with CVD,
whereas the role of TFPI in CVD is less clear [6].
Recently, the endogenous thrombin potentiale (ETP)
measured by the calibrated automated thrombogram
(CAT) assay, has been proposed to be an informative re-
search tool to study the degree of hypercoagulability [7].
There are however, limited data on the association be-
tween CAT measures and CVD risk factors.
Patients with coronary artery disease (CAD) are rou-
tinely treated with antiplatelet medication, of which
aspirin is most commonly used. Aspirin suppress
the cyclooxygenase pathway in the arachidonic acid
metabolism and has also been shown to possess anti-
inflammatory properties probably by inactivating NF-
kappa B [8,9]. Recently other anti-platelet drugs have
become common in use, for instance clopidogrel, a thie-
nopyridine, blocking the ADP-pathway. Since activated
platelets act as a catalytic surface for thrombin gener-
ation, anti-platelet treatment in general, might have an
anticoagulant effect, with a decline in generated throm-
bin [10]. However, limited knowledge of any effects on
prothrombotic markers of clopidogrel exists.
The aim of the present study was to investigate
whether prothrombotic markers were associated with
traditional risk factors, and clinical subgroups in a large
population with stable CAD. The state of hypercoagul-
ability was assessed by measures of sTF and TFPI, and
F1+2, D-dimer and the CAT assay, the latter as marker
of ex vivo thrombin generation.
We further wanted to explore the long-term effect of
single clopidogrel as compared to single aspirin treat-
ment on hypercoagulability in the same population, with




A total of 1001 patients with angiographically verified
stable CAD were enrolled in the ASpirin non-
responsiveness and Clopidogrel clinical Endpoint Trial
(ASCET) [11] at Oslo University Hospital, Ullevål, from
2004–2008. At inclusion all patients were on aspirin
only and had been treated with aspirin only (160 mg/
day) at least one week. Patients were thereafter rando-
mized to either continous treatment with aspirin or to
change to clopidogrel (75 mg/day) and the patients were
further followed for two years. The present sub-study is
based on data from baseline examinations in the total
population and from the one-year follow up in a sub-set
of 300 consecutively enrolled patients.
The study is in accordance with the principles of the
declaration of Helsinki and is approved by the Regional
Ethics Committee, and all patients have given written
informed consent to participate. The study is registered
at www.clinicaltrials.gov: NCT 00222261.
Clinical subgroups
Within the population, previous myocardial infarction
(MI) was recorded by patients’ medical files, and hyper-
tension (HT) was defined as previously diagnosed and
treated HT. Diabetes included individuals with treated
type 2 diabetes (T2DM) and/or fasting glucose
>7.0 mmol/L. The metabolic syndrome (MetS) was
defined according to the American Heart Association/
National Heart, Lung and Blood Institute [12]. Smoking
habits were recorded as current smokers or not. Ex-
smokers were included as non-smokers if they had quit
smoking >3 months ago.
Blood sampling
Venous blood samples were drawn in fasting condition
between 08:00 and 10:30 am before intake of morning
medication. Blood was collected in Vacutainer tubes
containing 0.129 M trisodium citrate in dilution 1:10.
The samples were stored on ice and centrifuged at 3000
x g for 20 min at 4°C within 1 hour. Plasma was kept
frozen at −80°C until analyzed. Blood samples for
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routine analysis (glucose, HbA1C and lipids) were pre-
pared and analyzed with conventional methods.
Laboratory methods
Levels of sTF, TFPI, F1+2 and D-dimer were assessed by
commercially available enzyme immunoassays; Imubind
TF kit recognizing TF-apolipoprotein, sTF and TF-VII
complexes (American Diagnostic Inc., Greenwich,
Conn., USA), Asserachrom free and total TFPI antigen,
recognizing full-length and full-length and truncated
TFPI molecules associated to lipoproteins, respectively
(Stago Diagnostica, Asniere, France), EnzygnostW F1+2
(monoclonal) (Siemens, Marburg, Germany) and Assera-
chromW D-dimer (Stago Diagnostica). The coefficients
of variation in our laboratory were 7.9, 5.6, 5.7 and 6.7%,
respectively.
The CAT assay
Ex vivo thrombin generation potential was investigated
by the CAT assay, performed according to the manufac-
turer’s instruction (Thrombinoscope BV, Maastricht, The
Netherlands). The method is described in detail else-
where [13]. Briefly, 80μl thawed platelet poor plasma
(PPP) was mixed with 20μl of a reagent containing re-
combinant relipidated TF and phospholipids, with the
final concentrations of 5pM and 4μM, respectively.
Reagents were provided from Thrombinoscope BV
(Maastricht, The Netherlands). The reactions were per-
formed in micro-titre wells (Immulon 2HB transparent
U-bottom from Thermo Electron, Denmark) after auto-
matic addition of a freshmade starting reagent contain-
ing CaCl2 (100 mM) and a thrombin specific fluorogenic
substrate (Z-Gly-Gly-Arg-AMC) (2.5 mM) in Hepes buf-
fer. The fluorescence intensity was recorded by the
Fluoroskan AscentW microplate fluorometer (Thermo
Fisher Scientific Oy, Vantaa, Finland). By simultaneous
analysis of an inert thrombin calibrator with known
thrombin activity, the software program (Thrombino-
scope BV, version 3.0.0.29) is enabled to display the
lag-time (LT, min), peak height (PeakH, nM), the en-
dogenous thrombin potential (ETP, nMmin) and time
to peak (ttPeak, min). The inter-assay coefficients of
variation for the different parameters were 14.2%, 4.6%,
5.0% and 8.0%, respectively.
Statistical methods
Continuous data on clinical characteristic of the popula-
tion were mostly normally distributed, and data are pre-
sented as mean (SD) or proportions. As most of the
measured variables were not normally distributed, data
are presented as median values with 25, 75 percentiles.
Univariate linear regression with log transformed values
when appropriate, were used to analyse for associations
between variables of thrombin generation and traditional
risk factors. Linear regression models were also used to
adjust for potential covariates in group comparisons.
Mann–Whitney U test or chi square test for categor-
ical data were applied for group comparisons, and Wil-
coxons test was used for within group changes. For
difference in changes between the intervention groups,
Mann–Whitney U test was used. P-values ≤0.05 were
considered statistically significant. The statistical ana-
lyses were performed by SPSS Inc PASW statistics, ver-
sion 18.
Results
Clinical and laboratory characteristics of the total study
population at baseline (n = 1001) are shown in Table 1.
Mean age was 62 years and 22% of the patients were
women. The patients were optimally treated, all receiv-
ing aspirin, 98% on statins, 76% on beta blockers and
50% on angiotensin converting enzyme inhibitors (ACEI)
or angiotensin receptor blocker (ARB).
Table 1 Baseline characteristics of the total study
population (n = 1001)
Age1 (years (range)) 62 (36–81)
Male / Female (n (%)) 783/218 (78/22)
Hypertension (n (%)) 555 (55)
Metabolic syndrome (n (%)) 244 (24)
Diabetes Mellitus (n (%)) 200 (20)
Previous MI (n (%)) 437 (44)
Current smokers (n (%)) 204 (20)
BMI (kg/m2) 27.4 ± 3.7
Fasting glucose (mmol/L) 6.02 ± 1.82
HbA1C (%) 5.96 ±0.87
CRP (mg/L) 2.23 (1.03, 4.11)
Total cholesterol (mmol/L) 4.55 ±0.98
HDL cholesterol (mmol/L) 1.34 ±0.41
LDL cholesterol (mmol/L) 2.53 ± 0.83
Triglycerides (mmol/L) 2 1.29 (0.93, 1.82)
SBP (mmHg) 139 ±19





ACEI / ARB 50
Nitrates 22
Values are mean (SD) and number (proportions) if not otherwise stated.
1 mean (range).
2 median (25, 75 percentiles).
Abbreviations: MI: myocardial infarction, BMI: Body Mass Index, SBP: systolic
blood pressure, DBP: diastolic blood pressure, ACEI: angiotensin converting
enzyme inhibitor, ARB: angiotensin receptor blocker.
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Associations
Associations between traditional risk factors and vari-
ables of thrombin generation are presented in Table 2.
Age was significantly associated with F1+2 and D-dimer
(p <0.001, both). Otherwise, only weak associations were
found. For parameters in the CAT assay no significant
associations were found (data not shown). Only results
of ETP from the CAT assay are presented further.
Thrombin generation in subgroups of CAD
The associations between different subgroups and sTF,
free and total TFPI have previously been reported [14].
Markers of thrombin generation according to subgroups
are presented in Table 3. Gender differences were
observed for F1+2 and D-dimer, showing women to have
higher levels, also after adjustment for covariates (age,
BMI and HDL-cholesterol) (p <0.001 and p = 0.033, re-
spectively). Smokers had significantly higher levels of
ETP as compared to non-smokers (adjusted p = 0.014).
In patients having MetS increased levels of ETP, but
lower levels of F1+2 were observed. However, these dif-
ferences were abolished after adjustments for covariates.
No significant differences in any variables were observed
with respect to having T2DM or not or whether they
had experienced a MI or not.
In univariate analyses significantly higher levels of F1+2
and D-dimer were observed in patients with HT, however,
not statistically significant in multivariate analyses. A high
number of patients were on ACEI and/or ARBS (n= 495)
and in these patients compared to non-users, significantly
higher levels of F1+2 and D-dimer were found. When
adjusted for covariates, including creatinine, F1+2 levels
were still significantly elevated (p= 0.013). No differences
in any variables in patients using beta-blockers or not
were observed.
Influence of aspirin and clopidogrel on markers
of coagulation
In the subset of patients (n = 300) of which 276 were
available for re-investigation after 12 months, baseline
characteristics did not differ between the randomized
groups (Additional file 1: Table S1). Of the measured
variables significantly higher levels of sTF in the clopido-
grel group were found at baseline (p <0.01) (Table 4).
After 12 months intervention, significant reduction in F1
+2 (p = 0.029) and ETP (p = 0.003) were observed within
the aspirin group, whereas a slight, but statistically sig-
nificant increase in sTF (p = 0.029) and free TFPI (p
<0.001) were recorded. In the group randomized to clo-
pidogrel, significantly reduced levels of ETP were found
(p <0.001), while levels of free TFPI increased
(p = 0.035). When comparing the changes between the
Table 2 Associations between variables of thrombin
generation and traditional risk factors in the total
population
F1+2 D-dimer ETP
beta p-value beta p-value beta p-value
Age 0.229 <0.001 0.417 <0.001 −0.026 0.424
Total cholesterol 0.102 0.001 0.051 0.110 0.060 0.062
HDL cholesterol 0.193 <0.001 0.131 <0.001 −0.133 <0.001
LDL cholesterol 0.050 0.120 0.048 0.134 0.089 0.006
Triglycerides −0.058 0.066 −0.088 0.005 0.095 0.003
HbA1C −0.063 0.047 0.044 0.164 0.077 0.016
Fasting glucose −0.053 0.092 0.030 0.344 0.074 0.020
BMI −0.125 <0.001 −0.043 0.177 0.072 0.024
Abbreviations: BMI: Body Mass Index.
Table 3 Variables of ex vivo and in vivo thrombin
generation in subgroups of patients with stable CAD
ETP F1+2 D-dimer
(nMmin) (pmol/L) (ng/ml)
Male (n = 771) 1439 (1240, 1599) 192 (146, 257) 381 (264, 595)
Female (n = 210) 1416 (1231, 1620) 251 (183, 356) 477 (338, 660)
p-value 0.745 <0.001 (<0.001*) <0.001 (0.033*)
Smoking - (n = 779) 1423 (1225, 1590) 205 (152, 276) 394 (279, 613)
Smoking+ (n = 202) 1466 (1291, 1633) 204 (153, 281) 419 (285, 609)
p-value 0.018 (0.014*) 0.789 0.605
MI - (n = 552) 1425 (1226, 1597) 202 (152, 277) 397 (273, 602)
MI + (n = 429) 1441 (1241, 1610) 206 (154, 277) 403 (285, 626)
p-value 0.325 0.567 0.428
T2DM - (n = 786) 1439 (1219, 1602) 207 (155, 278) 399 (278, 607)
T2DM+ (n= 195) 1427 (1279, 1597) 192 (145, 263) 391 (283, 616)
p-value 0.671 0.079 0.667
MetS - (n = 739) 1420 (1208, 1581) 207 (157, 287) 399 (277, 614)
MetS + (n = 241) 1504 (1301, 1654) 187 (143, 251) 400 (282, 603)
p-value <0.001 (0.283*) 0.002 (0.927*) 0.972
HT - (n = 436) 1430 (1224, 1603) 195 (148, 266) 377 (256, 583)
HT + (n = 545) 1440 (1246, 1601) 210 (156, 287) 419 (298, 625)
p-value 0.835 0.053 (0.532*) 0.01 (0.358*)
RAS inhib - (n = 491) 1440 (1210, 1619) 195 (145, 260) 383 (262, 561)
RAS inhib + (n = 483) 1436 (1245, 1590) 209 (159, 286) 419 (292, 658)
p-value 0.579 0.005 (0.013†) 0.001 (0.060†)
β-blockers - (n = 236) 1466 (1229, 1615) 200 (148, 258) 390 (267, 551)
β-blockers + (n = 737) 1433 (1239, 1600) 206 (153, 278) 401 (284, 626)
p-value 0.540 0.335 0.090
Medians (25, 75 percentiles) are given.
p-values refer to unadjusted differences between groups.
* Adjusted for age, BMI and HDL-cholesterol.
† Adjusted for age, BMI, HDL-cholesterol and creatinine.
Abbreviations: MI: myocardial infarction, T2DM: Type 2-diabetes mellitus, MetS:
metabolic syndrome, HT: hypertension, RAS: renin angiotensin system
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groups, the reduction in F1+2 levels in the aspirin group
was significantly different from the unchanged values in
the clopidogrel group (p = 0.023). As for sTF the slight
increase in the aspirin group was significantly different
from the non-significant reduction in the clopidogrel
group (p = 0.032). When taking the baseline levels into
account by analyzing the difference in relative changes,
the difference in change was still statistically significant
(p = 0.042).
Discussion
In the present study on patients with stable CAD we
could show that age was significantly associated to
in vivo thrombin generation assessed by F1+2 and D-
dimer. These markers were both higher in women than
in men, and smokers had elevated levels of ex vivo
thrombin generation measured by ETP, compared to
non-smokers. Patients on ACEI and/or ARBS had sig-
nificantly higher levels of F1+2 compared to non-users.
After one year treatment with either aspirin or clopi-
dogrel, ETP levels were significantly reduced in both
groups, and a significant reduction in F1+2 levels was
observed on aspirin in contrast to on clopidogrel. The
limited conformity between the investigated markers of
in vivo and ex vivo thrombin generation, indicate that
ongoing in vivo coagulation may not necessarily be com-
patible with a higher potential for ex vivo thrombin
generation.
Thrombin generation in subgroups of CAD
Among the traditional risk factors we found age to be
strongest associated with the prothrombotic markers F1
+2 and D-dimer. These results are in line with previous
reports, demonstrated in a wide age span in healthy indi-
viduals [15]. Although these markers are known to be
unspecific among the elderly, the risk of CVD in general
is more pronounced with advancing age, partly due to
an imbalance in the haemostatic system [16].
Regarding age and ex vivo thrombin generation (ETP)
we could not find any association. This is in contrast to
some previous reports, however, performed in quite dif-
ferent populations [17,18]. The discrepancy might be
due to the rather large inter-individual variations
reported for this assay, which may mask potential differ-
ences [7].
The women in our population were older compared to
men, and they presented with higher levels of F1+2 and
D-dimer, also after adjustment for age. ETP levels were,
however not affected. This is in line with results from
another similar group reporting elevated levels of pro-
thrombotic markers in women compared to men [19].
Most of our women were postmenopausal, which also is
associated with an adverse influence on traditional car-
diovascular risk factors [20].
We demonstrated increased ex vivo thrombin gener-
ation assessed by ETP in smokers. To the best of our
knowledge this has not been reported on before. In an
Italian study it was shown a reduction in F1+2 and D-
dimer levels after smoking cessation in individuals free
from cardiovascular risk factors [21]. It is well-known
that tobacco smoke increases platelet aggregability and it
is discussed to have a direct toxic effect on the endothe-
lium, including trigging haemostatic activation and
thrombosis [22,23].
We could not demonstrate any increased activation of
coagulation in patients with previous MI, T2DM or HT.
According to several lines of evidence such patients are
discussed to be more susceptible to atherothrombotic
disease [24,25]. However, all our patients were very well
medically treated, i.e. all patients were on aspirin and
98% on statins. Statins have been shown to reduce
hypercoagulability, which may have masked any differ-
ence [26].
Somehow unexpected, patients on renin-angiotensin
system (RAS) blockade, either with ACEI or ARB’s, had
elevated levels of F1+2 compared to non-users,
Table 4 Markers of coagulation at baseline (all patients on aspirin) and after 12 months continuing on aspirin or
randomized to clopidogrel
ASPIRIN (n = 145) CLOPIDOGREL (n = 131)
Baseline 12 months p1 Baseline 12 months p2 Δ p
F1+2 (pmol/L) 216 (157, 282) 196 (142, 261) 0.029 201 (149, 279) 205 (158, 340) 0.298 0.023
D-dimer (ng/ml) 424 (271, 642) 434 (309, 661) 0.189 399 (284, 603) 409 (277, 583) 0.405 0.129
ETP (nMmin) 1502 (1308, 1626) 1397 (1148, 1571) 0.003 1492 (1281, 1676) 1366 (1165, 1584) <0.001 0.687
sTF (pg/ml) 139 (91, 191) 143 (95, 206) 0.029 158* (120, 218) 154 (118, 222) 0.384 0.042†
TFPI (free) (ng/ml) 15.3 (12.3, 17.9) 16.7 (13.0, 20.6) <0.001 14.4 (11.4, 18.1) 15.3 (11.7, 18.6) 0.035 0.163
TFPI (total) (ng/ml) 68.4 (58.7, 76.6) 66.4 (58.6, 74.4) 0.190 66.1 (58.1, 76.6) 65.1 (57.9, 75.0) 0.130 0.864
Median values (25, 75 percentiles) are given.
* refers to differences between groups at baseline (p <0.01).
p1 and p2 refer to differences from baseline to 12 months in the aspirin and clopidogrel groups, respectively. Δ p refer to difference in changes between groups
from baseline to 12 months.
† refers to difference in relative changes from baseline to 12 months
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statistically significant also after correction for renal
function. RAS blockade has been shown to be protective
in different patient populations [27], possibly by
improved haemodynamic stability, but also by preven-
tion of angiotensin stimulated TF-expression and inhib-
ition of fibrinolysis [28-30]. It has been shown
significant correlations between components of the RAS,
and levels of D-dimer, fibrinogen and plasminogen acti-
vator inhibitor type-1 in hypertensive patients, and it
was suggested that plasma renin activity was the pre-
dominant component [31]. As renin is upstream of the
levels of the blocade used, the increased levels of F1+2
might be discussed to be due to less consumption of
renin.
Effect of aspirin and clopidogrel on haemostatic markers
Data on anticoagulant effect of single antiplatelet treat-
ment with either aspirin or clopidogrel, are sparse and
conflicting. We demonstrated reduced thrombin gener-
ation, measured by ETP and F1+2, after long-term treat-
ment with aspirin (160 mg/d), the latter being different
from the changes on clopidogrel. This can be seen as
contradictory to the CAPRIE trial in which clopidogrel
was found to be slightly more effective compared to as-
pirin [32]. In this trial it should be noted that there were
no difference in outcome between aspirin-or clopido-
grel-treated patients entering the study with CAD, being
present in all our patients. In addition to different
mechanisms for inhibition, the patient population may
thus also play a role for the effectiveness. In the present
study, only effects on haemostatic markers were investi-
gated. The effects on thrombin generation could poten-
tially be ascribed to anti-inflammatory actions of aspirin.
However, we have previously shown no difference in
CRP-levels between the aspirin and clopidogrel groups
in this cohort [9].
The decline in ETP could be explained by change in
the assembly of pro- and anticoagulant factors after
long-term treatment [13,33]. Activated platelets play a
crucial role as a catalytic surface and a source for acti-
vated coagulation factor V, necessary for the large scale
thrombin generation. During antiplatelet treatment this
might decrease levels of F1+2, the most sensitive marker
for in vivo thrombin generation [34]. Our results are in
accordance with some previous reports, although, con-
flicting results exist [10,35].
Decreased thrombin generation by aspirin at the site
of microvascular injury has furthermore been shown
[36,37]. Several other mechanisms in the anticoagulant
effect of aspirin have been discussed. The properties of
aspirin to acetylate coagulation proteins and platelet
receptors have been suggested to play a role [38]. It has
moreover been shown decreased TF expression after
treatment with aspirin in an experimental study related
to reduced activity of the transcription factor NF-kappa
B [39,40]. In our study, we observed a small but statisti-
cally significant increase in endogenous TF after
12 months on aspirin. This was not visualized in the
CAT assay, which may be due to the relatively high dose
of thrombin used in the assay.
In the group randomized to clopidogrel (75 mg/d) we
observed a decline in thrombin generation after
12 months, however, only shown by ETP. Limited data
on single long-term clopidogrel administration exist, but
anti-thrombotic properties of clopidogrel has been
shown at the site of microvascular injury in CAD
patients [41]. In a rat modell a 23% decrease in ETP
after clopidogrel ingestion, has also been shown [42]. On
the contrary, several studies including dual anti-platelet
treatment have not been able to demonstrate an add-
itional beneficial effect of clopidogrel on top of aspirin
on thrombin generation [43-45]. Blocking the ADP-
pathway has nevertheless been shown to decrease colla-
gen stimulated release of TF from platelet-leukocyte
aggregates, and clopidogrel alone, as well as in combin-
ation with other antiplatelet agents, was reported to de-
crease circulating levels of TF [46,47]. This could not be
confirmed in our study. This might be discussed along
with the different TF methods used [47,48].
Free TFPI levels increased in both treatment groups.
Whether this elevation is a compensatory mechanism to
maintain the TF/TFPI balance is not known [49]. TFPI
is a major determinant of ex vivo thrombin generation
tests and might therefore explain the decrease in ETP
levels, seen after one year in both groups [50].
Conclusions
In summary, in the present population with stable CAD,
we could demonstrate a more hypercoagulable profile
among women, smokers and patients on RAS medica-
tion, assessed by the prothrombotic markers F1+2, D-
dimer and ETP. Long-term antiplatelet treatment with
aspirin alone seems to attenuate thrombin generation to
a greater extent than with clopidogrel alone.
Additional file
Additional file 1: Table S1. Baseline characteristics according to the
randomized groups. Values are mean (SD) and proportions if not
otherwise stated.
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